KRAS and cancer: The results indicate that these eight oncogenes – EBAG9, MTDH, ATP6V1C1, OPA1, ATCL6A, BCL6, SENP5 and KRAS are likely to be important cross- cancer target genes for cancer therapies and may also be associated with the patient’s survival rate.